Recor Medical, Inc : Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
The age of renal denervation as a treatment for hypertension may have finally arrived in the U.S. with the affirmative U.S. FDA advisory vote for the Paradise system for renal denervation by Recor Medical Inc., of Palo Alto, Calif. The 12-member advisory committee vote unanimously that the data suggested the ultrasound-based device was safe and voted 8-3 in support of the Paradise’s efficacy, an outcome that the agency may find difficult to refute, given the large public health impact of hypertension in the U.S.
ReCor Medical, Inc : ReCor Responds to European Society of Hypertension s (ESH) Updated Guidelines for Management of Arterial Hypertension finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Treating hypertension is complex, and European guidelines reinforce the safety and effectiveness of renal denervation as a treatment option to improve hypertension controlPALO ALTO, Calif. (BUSINESS WIRE) ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Device.
This channel includes news and new technology innovations for renal denervation used to treat hypertension. Renal denervation is a catheter-based therapy. The catheter is into the renal artery and delivers radio-frequency energy to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys. This enables greater filtration of the blood and removal of excess water that causes hypertension.